By day 20 (survival endpoint for mice with HBSS treated TRAMP-C2 tumors), ADU reduced tumor volume by 67% and combination of ADU with IL-15 by 71% compared with vehicle; both treatments increased survival to 33 and 45 days respectively (Figures 1E–H). The gene discussed is IL15; the disease is neoplasm.